IWATE MEDICAL UNIVERSITY

Combination Therapies Reshape Frontline HCC Treatment Landscape

6 months ago

• Combination regimens, including STRIDE (single tremelimumab and regular-interval durvalumab), are transforming first-line HCC treatment, offering personalized options. • HIMALAYA trial's 5-year data showed STRIDE achieved a median OS of 16.43 months versus 13.77 months with sorafenib, marking the longest follow-up in unresectable HCC. • LEAP-012 study indicated that lenvatinib plus pembrolizumab and TACE improved median PFS to 14.6 months compared to 10.0 months with TACE alone. • Real-world data from the STELLAR trial supports the use of TKIs like lenvatinib for patients ineligible for or failing immunotherapy, showing manageable safety profiles.